It is a long way to go public, and the valuation of Neuralink, a brain-computer interface company under the name of Maks, has reached 5 billion US dollars.

CTOnews.com June 5 news, Musk's brain-computer interface start-up Neuralink after two years ago completed private equity financing valuation of nearly $2 billion. Neuralink is now valued at around $5 billion after several private deals, according to Reuters.

On May 25, Neuralink announced that it had received approval from the U.S. Food and Drug Administration (FDA) and would subsequently launch its first human clinical study. This means Neuralink will implant their device into the human brain. As a result, a large number of investors have bought into it, causing its valuation to rise sharply in recent months.

Experts say it could take years for Neuralink to get a commercial license. Kip Ludwig, former director of neuroengineering at the National Institutes of Health, said he was "optimistic" that Neuralink would take at least 10 years to commercialize its brain-machine technology, and that the company faced other challenges, including a federal investigation into how its animal research was handled.

Neuralink sold privately to investors on the secondary market in recent days at a valuation of $7 billion, or $55 a share, after approval of human trials, according to an email seen by Reuters, although Reuters could not determine whether anyone bought at that offer. Neuralink executives and Musk did not respond to requests for comment.